Current treatment strategy of diffuse large B-cell lymphomas

@article{Niitsu2010CurrentTS,
  title={Current treatment strategy of diffuse large B-cell lymphomas},
  author={Nozomi Niitsu},
  journal={International Journal of Hematology},
  year={2010},
  volume={92},
  pages={231-237}
}
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin’s lymphoma, accounting for approximately 25–30% of all new patients. Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. Rituximab significantly improves treatment outcome in DLBCL. A large-phase III study demonstrated improved overall survival (OS) in patients with DLBCL treated with R-CHOP therapy… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Pathology of B-cell lymphomas: diagnosis and biomarker discovery.

  • Cancer treatment and research
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

Review on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor Treatment

  • Evidence-based complementary and alternative medicine : eCAM
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND